Selank Benefits: What Studies Report

Selank is a synthetic heptapeptide derived from a fragment of the endogenous peptide tuftsin. Discussions of its uses almost always circle back to one outcome domain: anxiety. The sections below group what published studies actually measured, name the study type and population, and state the reported direction of effect. Where a commonly searched benefit has little or no published support, that is stated plainly rather than filled in with speculation.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. It describes what researchers reported, not what any individual should do.

How to Read the Selank Evidence Base

Three features shape every honest summary of this compound. First, the clinical literature is small and concentrated in Russian-language psychiatry journals, where researchers evaluated selank in anxiety disorders and neurasthenia (PMID 18454096). Second, a meaningful share of the mechanistic and behavioural work is experimental animal research, including studies of learning and memory processes (PMID 20919548) and of withdrawal in rats with stable alcoholic motivation (PMID 24913576). Third, animal findings describe animals. They generate hypotheses about human physiology; they do not establish human outcomes.

Anxiety and Neurasthenia: The Most Studied Domain

The clearest line of human investigation concerns anxiety. A 2008 paper in a Russian psychiatry journal examined the efficacy and possible mechanisms of action of selank, described there as a new peptide anxiolytic, in the therapy of generalised anxiety disorders and neurasthenia (PMID 18454096). That framing matters: the study was designed around a clinical anxiety population, not around healthy volunteers seeking general calm or focus.

A later 2015 report addressed the optimisation of treatment of anxiety disorders with selank, again in a clinical psychiatry context (PMID 26356395). Papers written as optimisation reports typically examine how an agent fits alongside existing treatment approaches rather than testing it in isolation against placebo, which limits how far the findings can be generalised.

What this body of work does not contain is a large, multicentre, placebo controlled trial programme of the kind used to register conventional anxiolytics in the United States or the European Union. The reports cited above were published in a single national literature over roughly a seven year span, and readers evaluating selank should weigh that concentration when interpreting the reported anxiolytic effect (PMID 26356395).

The Comparison With Phenazepam

One of the more frequently referenced studies compared the anxiolytic effect and tolerability of selank with phenazepam, a benzodiazepine, in the treatment of anxiety disorders (PMID 25176261). Comparative designs of this type are useful because they place a candidate agent against an active reference rather than against nothing, and because tolerability is assessed in both arms.

Interest in this comparison usually stems from the known liabilities of benzodiazepines, including sedation, cognitive dulling, tolerance and dependence. The published comparison examined anxiolytic effect alongside tolerability in an anxiety disorder population (PMID 25176261), but a single comparative study in a specialised literature is not equivalent to the long term safety database that exists for registered medicines. No conclusion about relative safety over months or years can be drawn from the studies listed here.

Learning, Memory and Cognition: Experimental Work Only

Selank is often discussed as a nootropic. The verified literature supporting that framing is experimental rather than clinical. A 2010 experimental paper examined the optimisation of learning and memory processes by selank (PMID 20919548). Work of this kind is typically conducted in laboratory animals using behavioural tasks such as maze learning or conditioned avoidance, and the reported outcome describes performance in those tasks under the conditions the researchers set.

Several points follow. Behavioural task performance in a laboratory model is not the same construct as memory, concentration or productivity in a healthy adult human. There is no trial in this verified set that measured cognitive performance in healthy human volunteers. Anyone citing selank as a cognitive enhancer for everyday use is extending beyond what the experimental learning and memory report actually measured (PMID 20919548).

Alcohol Withdrawal Models: Animal Research

A 2014 study published in the Bulletin of Experimental Biology and Medicine evaluated the efficacy of the peptide anxiolytic selank during modelling of withdrawal syndrome in rats with stable alcoholic motivation (PMID 24913576). The population was rodent, the exposure was experimental, and the outcome was behaviour during a modelled withdrawal state.

This study is sometimes cited online as evidence that selank helps with alcohol dependence or withdrawal in people. The study did not involve people (PMID 24913576). Alcohol withdrawal in humans can be medically serious and is managed under clinical supervision; nothing in this animal literature speaks to that setting.

Benefits Frequently Searched For That the Verified Literature Does Not Cover

Several outcomes attached to selank in online discussion are not represented in the studies summarised on this page. Stating that plainly is more useful than inference.

• Sleep quality: no study in this verified set measured sleep architecture or insomnia outcomes. The clinical reports available addressed anxiety disorders and neurasthenia (PMID 18454096).
• Depression as a primary outcome: the clinical work cited here was framed around anxiety disorders rather than major depressive disorder (PMID 26356395).
• Immune function: selank derives from tuftsin, a peptide with immunological associations, but no immunological outcome was measured in the studies cited on this page, which covered anxiety, learning and memory, and a withdrawal model (PMID 20919548).
• Tissue repair, tendon or joint recovery: a 2026 review examined therapeutic peptides in orthopaedics, including applications, challenges and future directions for that field (PMID 41490200), while the selank studies cited here reported neuropsychiatric and behavioural outcomes rather than musculoskeletal ones (PMID 24913576).
• Body composition, athletic performance, longevity: no study in this set measured any of these endpoints.

Tolerability and Adverse Events: What Studies Report

Tolerability was an explicit endpoint in the comparative study of selank and phenazepam in anxiety disorders, where researchers assessed it alongside the anxiolytic effect (PMID 25176261). The 2008 clinical report similarly addressed efficacy and possible mechanisms in generalised anxiety disorders and neurasthenia (PMID 18454096).

Important limits apply to any safety reading. The clinical studies available were small relative to modern registration trials, were conducted within one national research literature, and ran over treatment courses measured in weeks rather than years (PMID 26356395). Rare adverse events, interactions with other medicines, effects in pregnancy, and effects in older adults or people with hepatic or renal impairment were not characterised in the studies summarised here. Absence of reported harm in a small study set is not the same as demonstrated safety.

Why Dosing Is Not Described on This Page

Dosing information is only reproduced on PeptideU when a verified citation supports the specific figure in the same passage. The verified papers behind this page are indexed by title and journal, and no dose, route or treatment duration is reproduced here because doing so would mean stating a number the citation set cannot support (PMID 25176261). Readers encountering confident dosing charts for selank on other sites should check whether each number is traceable to a named study.

Regulatory Status

Selank is not an approved medicine in the United States. It has no FDA approval for any indication, is not an established pharmacy compounding item in that jurisdiction, and material offered under its name is typically labelled for research use only. The clinical literature that exists was generated within a different regulatory environment from the one that governs prescription medicines in the United States or the European Union (PMID 18454096). Regulatory status differs by country and can change.

What a Careful Reader Can Conclude

Taken together, the verified literature supports a narrow statement: selank has been studied as a peptide anxiolytic in clinical anxiety populations, including a direct comparison with a benzodiazepine (PMID 25176261), and has been examined in experimental animal work on learning and memory (PMID 20919548) and on modelled alcohol withdrawal (PMID 24913576). Beyond that, the evidence thins quickly. Broader claims about cognition in healthy adults, mood disorders, sleep, immunity or recovery are extrapolations rather than findings. Any decision involving an unapproved compound belongs with a licensed physician who knows the individual's medical history.

References

• [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia] (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2008)
• [Experimental optimization of learning and memory processes by selank] (Eksperimental'naia i klinicheskaia farmakologiia, 2010)
• Efficacy of peptide anxiolytic selank during modeling of withdrawal syndrome in rats with stable alcoholic motivation (Bulletin of Experimental Biology and Medicine, 2014)
• [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders] (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2014)
• [Optimization of the treatment of anxiety disorders with selank] (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2015)
• Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (JAAOS Global Research and Reviews, 2026)